Solid Organ Transplantation

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/88

encourage image

There's no tags or description

Looks like no tags are added yet.

89 Terms

1
New cards

two to four

- triple therapy for maintenance phase: corticosteroid, CNI, anti-proliferative

Generally, patients receive a combination of ____ immunosuppressive drugs in order to minimize individual drug toxicities as well as block different pathways of the immune response

2
New cards

Calcineurin inhibitors (CNI): tacrolimus and cyclosporine

____ are the most commonly used immunosuppressive regimens, but they are associated with serious adverse effects

3
New cards

nephrotoxicity

Calcineurin inhibitor-induced ____ is one of the most common adverse effects observed in solid-organ transplant recipients

4
New cards

Corticosteroids

____ are first-line treatment for allograft rejection

5
New cards

Bone marrow suppression

Azathioprine and mycophenolic acid derivatives inhibit T-cell proliferation by altering purine synthesis. ____ is the most significant adverse effect associated with these agents.

6
New cards

cardiac transplantation

Treatment of choice for patients with severe end-stage heart failure.

7
New cards

- Candidates generally present with NYHA class III or IV symptoms and EF <20%

- General indications: rapidly declining cardiac function, requirement of IV inotropes, and a projected 1-year mortality rate of greater than 75%

General presentation and indications for cardiac transplantation

8
New cards

- Acute hepatic necrosis: chronic or acute hepatitis B or C

- Neoplasms: hepatoma, cholangiocarcinoma

Indications for liver transplantation

- may involve the use of the entire organ or a segment

9
New cards

- Cystic fibrosis, emphysema/chronic obstructive pulmonary disease

Indications for lung transplantation

- may involve deceased donation of two lungs or a single lung

10
New cards

DM, glomerular diseases (Goodpasture syndrome), hypertension, neoplasm (ie, renal cell carcinoma), polycystic kidney disease

Indications for kidney transplantation

11
New cards

true, if they are healthy enough to undergo surgery

- 700,000+ patients are living with ESRD in the US today

T/F: All patients with ESRD should be considered for renal transplantation.

12
New cards

Autograft

- antigen present in autograft is the same as that present in body (skin), so the immune system recognizes the autograft antigen as a self antigen and no immune response is elicited.

Self-tissue is transferred from one body site to another

13
New cards

Syngeneic graft (isograft)

- no immune response is elicited

Grafts transplanted between two genetically identical individuals of the same species (twins)

14
New cards

Allograft

- An immune response is elicited

Grafts between members of the same species genetically different; most common form

15
New cards

Xenograft

- An immune response is elicited

Tissue or organs from an individual of one species transplanted into or grafted onto an organism of another species (ex: pig heart valve)

16
New cards

Hyperacute rejection

- uncommon due to routine pretransplant surveillance testing

Rejection that may be evident within minutes of the transplantation procedure when preformed donor-specific antibodies are present in the recipient at the time of the transplant

- Ischemic damage to the microvasculature rapidly results in tissue necrosis

- Organ must be removed immediately to prevent severe systemic responses

17
New cards

Acute cellular rejection

Rejection that usually occurs in the first few months following transplantation, but can occur at any time during the life of the allograft

18
New cards

T-lymphocytes

Acute cellular rejection is mediated by alloreactive ____ that appear in the circulation and infiltrate the allograft through the vascular endothelium

- cytotoxic cells specifically target and kill the functioning cells in the allograft

19
New cards

30%

Acute cellular rejection of a kidney transplant can affect up to 20% of patients during the first 6 months following transplantation. Rejection is evidenced by an abrupt rise in serum creatinine concentration ≥____% over baseline.

20
New cards

1. High-dose steroids (pulse with subsequent taper)

- Three daily intravenous pulses of 500, 250, and 250 mg methylprednisolone intraoperatively and on postoperative days 1 and 2

- Taper CS dose to 20 mg oral methylprednisolone per day for 2-4 wk following transplant.

2. Addition of another immunosuppressant indefinitely

3. Short-term treatment with a polyclonal or monoclonal antibody

Treatment of acute cellular rejection post-transplant

21
New cards

Humoral rejection

Rejection characterized by the presence of antibodies directed against HLA antigens present on the donor vascular endothelium

22
New cards

Acute antibody-mediated rejection

- Less common than cell-mediated rejection

Type of rejection in which antibodies activate complement, creating a membrane attack complex that directly damages the organ and attracts inflammatory cells to the allograft

- Damage is distinct from cellular rejection and involves microvascular injury, often to the peritubular capillaries

- Usually occurs in the first 3 months after transplantation

- Associated with an increased fatality rate

23
New cards

Chronic rejection

Major cause of graft-loss; occurs ≥1 year post-transplant; slow, insidious form of acute rejection, resulting in worsening organ function over time

24
New cards

HTN, proteinuria, and progressive decline in kidney function

What is the classic triad of chronic allograft nephropathy?

25
New cards

Retransplantation

What is the only effective treatment option for chronic rejection?

26
New cards

Induction therapy

Provides a high level of immunosuppression in the early posttransplant period, when the risk of acute rejection is highest; given before or at the time of transplant to prevent acute rejection

27
New cards

Maintenance immunosuppression

Prevent acute and chronic rejection while minimizing drug-related toxicity

28
New cards

1. Non-depleting agent: Basiliximab (Simulect)

2. Depleting agents:

- Polyclonal antibodies: antithrombocyte globulin rabbit and equine

- Monoclonal antibodies: Alemtuzumab (Compath)

Induction agents

29
New cards

Antithymocyte globulin IV for 5-10 days for induction

- Atgam: equine polyclonal antibody

- Thymoglobulin: rabbit polyclonal antibody (less immunogenic, more potent)

Depleting antibody used as an induction agent and is also approved for corticosteroid-resistant rejection

30
New cards

1. Infusion-related reactions: fever, chills, pruritus, hypotension

- pretreat with Diphenhydramine, Acetaminophen, and corticosteroids

2. Dose-limiting myelosuppression

3. Infections

4. Malignancy

SEs of Antithymocyte globulin (Atgam, Thymoglobulin)

31
New cards

Administer under the supervision of a physician experienced in immunosuppressive therapy. Supportive medical resources (epinephrine) must be readily available. Anaphylaxis can occur.

BBW for Antithymocyte globulin (Atgam, Thymoglobulin)

32
New cards

Alemtuzumab (Compath)

Depleting antibody that is commonly used for treatment of acute rejection and induction (not FDA-approved uses)

- FDA-approved for B-cell chronic lymphocytic leukemia

- Humanized mab against CD52 surface antigen found on T and B lymphocytes

33
New cards

Neutropenia, thrombocytopenia, anemia, n/v/d, HA, dizziness

SEs of Alemtuzumab (Compath)

34
New cards

Basiliximab (Simulect) given 2 hours prior to transplant, followed by a dose on post-op days 2 and 4

Non-depleting IL-2 receptor antagonist that is the most commonly used induction drug

35
New cards

HTN, fever, stomach upset, n/v, edema, dyspnea, tremor

SEs of Basiliximab (Simulect)

36
New cards

Use only by physicians experienced in immunosuppressive therapy

BBW on Basiliximab (Simulect)

37
New cards

Calcineurin Inhibitors: Tacrolimus and Cyclosporine

Which class of medication is first-line for maintenance therapy post-transplant?

38
New cards

protein

Both calcineurin inhibitors are highly ___ bound

39
New cards

3A4 and P-gp

The calcineurin inhibitors are extensively metabolized by:

40
New cards

82%

Diltiazem, Verapamil, and Erythromycin (inhibitors) can increase the concentration of the calcineurin inhibitors by ____%

41
New cards

50%

Phenytoin and Rifampin (inducers) can decrease the concentration of the calcineurin inhibitors by ____%

42
New cards

nephrotoxicity

Major disadvantage of the calcineurin inhibitors

43
New cards

1. Delaying administration immediately post-op in patients at risk for nephrotoxicity (using an IL-2 Receptor Antagonist or Antilymphocyte globulin)

2. Monitoring trough blood concentrations

3. Reducing the dose

4. Avoiding other nephrotoxins: aminoglycosides, amphotericin B, NSAIDs

Ways to reduce nephrotoxicity with the calcineurin inhibitors:

44
New cards

Tacrolimus

- Prograf: IR capsule BID dosing; oral packet; IV injection

- Astagraf XL capsules: take every morning on an empty stomach (1-2 hours after a meal)

- Envarsus XR tablets: take once daily in the morning

First-line medication for maintenance post-transplant

45
New cards

1. Astagraf XL: Increased mortality in female liver transplant patients

2. Malignancy and serious infections

BBWs for Tacrolimus (Prograf, Astagraf XL, Envarsus XR)

46
New cards

SEs

- HTN

- Hyperglycemia (post-transplant diabetes)

- Neurotoxicity: tremor, HA, dizziness, seizures

- Nephrotoxicity (less than Cyclosporine

- QT prolongation

- Edema

- Insomnia

- Chest pain

- Diarrhea

- Anemia, leukopenia, thrombocytopenia

- Alopecia

- Infections

Monitoring: CBC, SCr, BUN, BP, BG, lipids, trough

SEs and monitoring parameters for Tacrolimus (Prograf, Astagraf XL, Envarsus XR)

47
New cards

5-12 ng/ml

Trough level for Tacrolimus (Prograf, Astagraf XL, Envarsus XR)

48
New cards

Sandimmune (non-modified)

- capsule, oral solution, IV injection (1/3 of PO dose)

Cyclosporine formulation with significant variability in absorption; mixes poorly with GI fluids, causing low and inconsistent absorption

49
New cards

Neoral, Gengraf

- capsule, oral solution

Modified cyclosporine microemulsion formulations that have higher and more consistent absorption

50
New cards

True, they cannot be used interchangeably.

T/F: Neoral/Gengraf (cyclosporine modified) and Sandimmune (cyclosporine non-modified) are not bioequivalent.

51
New cards

100-400 ng/ml

(nephrotoxicity can occur at any level)

Trough level for Cyclosporine (Sandimmune, Neoral, Gengraf)

52
New cards

SEs:

- HTN (more than Tacrolimus)

- Hyperkalemia, Hypomagnesemia

- Hirsutism

- Gingival hyperplasia

- Increased triglycerides

- QT prolongation

- Viral infections

- Anemia, Leukopenia, Thrombocytopenia

Monitoring: trough levels, serum electrolytes, CBC, renal function, LFTs, BP, lipid profile

SEs and monitoring parameters for Cyclosporine (Sandimmune, Neoral, Gengraf)

53
New cards

1. Hypertension and Nephrotoxicity

2. Immunosuppression: increased risk of lymphoma and other malignancies (skin cancer)

3. Experienced physician: only health care providers experienced in the management of systemic immunosuppressive therapy for the indicated disease should prescribe cyclosporine

4. Bioavailability: Sandimmune capsules and oral solution have decreased bioavailability in comparison with Gengraf and Neoral capsules and Gengraf and Neoral oral solution

BBWs on Cyclosporine (Sandimmune, Neoral, Gengraf)

54
New cards

Azathioprine (Imuran)

- tablets, IV

Antimetabolite, antiproliferative agent that is a prodrug of 6-mercaptopurine and inhibits T-lymphocyte proliferation by altering purine synthesis

- used in maintenance therapy as an alternative to Mycophenolate mofetil

55
New cards

Dose-limiting: leukopenia, anemia, thrombocytopenia

- occur within the first few weeks of therapy; can be managed by a dose reduction of AZA or discontinuation

Other SEs:

- N/v (take with food)

- Alopecia

- Hepatotoxicity

- Pancreatitis

SEs of Azathioprine (Imuran)

56
New cards

Increased risk of malignancy and hematologic toxicities

BBW on Azathioprine (Imuran)

57
New cards

Xanthine oxidase inhibitors: Allopurinol, Feboxustat

_____ can increase Azathioprine (Imuran) and 6-MP concentrations by four-fold if administered together; reduce the dose of AZA by 50-75% when used concurrently.

58
New cards

Mycophenolate mofetil

- Cellcept: tablet, capsule, suspension, IV injection

- Myfortic: enteric-coated tablets (reduces GI upset)

First-line antiproliferative (antimetabolite) agent for maintenance immunosuppression in solid organ transplantation

59
New cards

Most common: GI upset → n/v/d, abdominal pain

Other SEs: bone marrow suppression, edema

Monitoring: CBC, intolerable diarrhea, SCr, LFTs, signs of infection

SEs and monitoring parameters for Mycophenolate mofetil (Cellcept, Myfortic)

60
New cards

1. Experienced physician (Myfortic): only healthcare providers experienced in immunosuppressive therapy and management of organ transplant patients should prescribe Mycophenolate

2. Serious infections

3. Malignancies

4. Embryo-fetal toxicity: use during pregnancy is associated with increased risks of first-trimester pregnancy loss and congenital malformations

- The REMS program recommends discontinuing mycophenolate in females at least 6 weeks before pregnancy is attempted

BBWs on Mycophenolate mofetil (Cellcept, Myfortic)

61
New cards

1. Aluminum and magnesium-containing antacids

2. Cholestyramine

3. PPIs decrease levels of Mycophenolate

DDIs with Mycophenolate mofetil (Cellcept, Myfortic)

62
New cards

light

- dispense in a light-resistant container

Mycophenolate mofetil (Cellcept, Myfortic) tablets must be protected from ____.

63
New cards

D5W

Cellcept (IV) is only stable in _____

64
New cards

Mamalian Target of Rapamycin (mTOR) Inhibitors

1. Everolimus (Zortress): DOC

- improved PKs, shorter half-life, steady state is reached faster

- tablets

- NO loading dose necessary

2. Sirolumus (Rapamune)

- tablets, oral solution

- loading dose recommended

Class of medications that can be used in place of Calcineurin Inhibitors to lower the risk of nephrotoxicity or can be used concurrently with CNIs instead of an antiproliferative

65
New cards

CYP3A4 and P-gp

The mTOR inhibitors are extensively metabolized by:

66
New cards

3 months

The mTOR inhibitors cause delayed wound healing (more with Sirolimus); start these drugs ____ months after transplantation.

67
New cards

Hyperlipidemia; Pravastatin is the DOC due to no DDIs

What is a major side effect of the mTOR inhibitors? How is it managed?

68
New cards

Most common: leukopenia, thrombocytopenia, hyperlipidemia

Other: anemia, diarrhea, arthralgias, rash, HTN, proteinuria, pneumonitis (more common with Sirolimus; d/c if this develops), stomatitis, nephrotoxicity (more with Sirolimus), angioedema (especially with an ACEi), hyperglycemia (Everolimus)

SEs of the mTOR inhibitors

69
New cards

1. Immunosuppression: infection, malignancy (lymphoma, skin cancer)

2. Kidney graft thrombosis: increased risk of kidney arterial and venous thrombosis, resulting in graft loss, was reported, mostly within the first 30 days post-transplantation

3. Nephrotoxicity: can occur with the use of standard doses of cyclosporine in combination with everolimus; reduce dose of cyclosporine when used in combination with everolimus

4. Mortality in heart transplant: use in heart transplantation is not recommended.

BBWs on Everolimus (Zortress)

70
New cards

1. Immunosuppression: infection, malignancy (lymphoma)

2. Use is not recommended in lung and liver transplantation

3. Experienced physician

BBWs on Sirolimus (Rapamune)

71
New cards

Methylprednisolone and Prednisone

- High-dose IV methylprednisolone (250-1000 mg) is given at the time of transplantation, and the dose is tapered rapidly and usually discontinued within 3-5 days when oral prednisone is initiated. Taper over several weeks to months

Corticosteroids are the cornerstone of immunosuppression regimens. 30% of liver and 60% of kidney transplant patients receive corticosteroids for at least the first year after transplantation. What are the most commonly used corticosteroids?

72
New cards

Belatacept (Nulojix) IV infusion monthly

- requires access to an infusion center or a home infusion service to ensure appropriate administration

Co-stimulatory signal inhibitor that is the first IV biological maintenance immunosuppressive agent in renal transplant patients only

- may be used in place of CNIs

73
New cards

- Infections: UTI, URTI

- GI upset: nv/d/c

- Hyper or hypokalemia

- HA

- Peripheral edema

- Anemia, leukopenia

- Hypotension

- Arthralgia

- Insomnia

SEs of Belatacept (Nulojix)

74
New cards

Increased risk for serious infections, malignancies, and post-transplant lymphoproliferative disorder, with the highest risk in EBV-naive patients

- use only in EBV seropositive patients

BBW on Belatacept (Nulojix)

75
New cards

DHP CCBs: Amlodipine or Felodipine

- Goal BP in all renal transplant patients: <130/80

Cardiovascular disease is the leading cause of morbidity and mortality in transplant patients. Hypertension can be caused by corticosteroid use, use of cyclosporine or tacrolimus, and impaired kidney graft function. What is the preferred antihypertensive in transplant patients? What is the goal BP?

76
New cards

cholesterol >200 mg/dL

TG > 350 mg/dL

Cardiovascular disease is the leading cause of morbidity and mortality in transplant patients. Dyslipidemia can be caused by the use of corticosteroids, CNIs, and mTOR inhibitors. The risk of IHD is doubled with serum cholesterol >___ mg/dL or TGs >____ mg/dL

77
New cards

Pravastatin

- no interactions because it is not metabolized by CYP3A4

- monitor for rhabdo and increased LFTs

Cardiovascular disease is the leading cause of morbidity and mortality in transplant patients. Dyslipidemia can be caused by the use of corticosteroids, CNIs, and mTOR inhibitors. What is the drug of choice for dyslipidemia in transplant patients?

78
New cards

- More than 40% will require insulin

- Oral agent: Glipizide

- Use Metformin with caution due to the risk of lactic acidosis in those with impaired kidney function

Corticosteroids and CNIs (Tacrolimus) can impair glucose control in patients with pre-existing diabetes and can also cause new-onset diabetes after transplantation in 5-30% of patients. Other risk factors for diabetes include: AA or Hispanic ethnicity, age >40 at time of transplant, family history, and weight. What is the preferred treatment for diabetes in post-transplant patients?

79
New cards

opportunistic

- Pneumocystis jirovecii pneumonia

- Cytomegalovirus

Prophylactic therapy for ____ infections is started in all transplant patients.

80
New cards

6 months

Prophylactic therapy for Pneumocystis jirovecii pneumonia is continued for ____ months after transplant.

81
New cards

Bactrim DS once daily

- continued for 6-12 months after transplant

- monitor for myelosuppression, nephrotoxicity, rash, and photosensitivity

- alternatives: Dapsone, Atovaquone

DOC for Pneumocystis jirovecii pneumonia prophylaxis

82
New cards

3-6 months

Prophylactic therapy for cytomegalovirus usually occurs within the first ____ months post-transplantation.

83
New cards

200 days (can be used for longer)

Prophylactic therapy for cytomegalovirus usually occurs within the first 3-6 months post-transplantation and continued for the first ____ days.

84
New cards

1. Valganciclovir (Valcyte) 450-900 mg PO QD

2. Ganciclovir (Cytovene) 5 mg/kg IV daily

DOC for cytomegalovirus prophylaxis

85
New cards

Polyomavirus-associated

_____-associated nephropathy is an important case of impaired kidney function in kidney transplant recipients; it is caused by the BK virus that is reactivated in immunocompromised patients.

86
New cards

BK virus

Patients should be screened for urinary ____ virus replication montly for the first 3-6 months after transplant, and every 3 months thereafter for the first year.

87
New cards

Reduce immunosuppressive medications/doses or add Cidofovir

First-line treatment for the polyoma virus

88
New cards

skin cancer

Most common type of cancer in transplant patients

89
New cards

kidney

The risk of lung and colon cancers is nearly doubled in ____ transplant recipients.